Induction of liver monooxygenases by annatto and bixin in female rats

合集下载

肝纤维化的英文名词解释

肝纤维化的英文名词解释

肝纤维化的英文名词解释Liver Fibrosis: An In-depth ExplorationIntroduction:Liver fibrosis, also known as hepatic fibrosis, refers to the excessive accumulation of extracellular matrix proteins—particularly collagen—in the liver, resulting in the progressive scarring and stiffening of the organ. It develops as a response to chronic liver injury and can eventually lead to cirrhosis if left untreated. In this article, we aim to provide a comprehensive understanding of liver fibrosis, its causes, progression, and potential treatments.Causes of Liver Fibrosis:Liver fibrosis can be caused by various factors, including chronic viral hepatitis B and C, excessive alcohol consumption, non-alcoholic fatty liver disease (NAFLD), autoimmunity disorders, and drug-induced liver injury. These conditions trigger an immune response, leading to inflammation and the activation of hepatic stellate cells—the primary cells involved in fibrogenesis.Progression of Liver Fibrosis:Liver fibrosis typically progresses through several stages, characterized by the accumulation of connective tissue and architectural changes in the liver. These stages are usually assessed using a scoring system known as the METAVIR or Ishak scoring system, which grades fibrosis from F0 (no fibrosis) to F4 (cirrhosis).Stage 1 (F1): Portal Fibrosis with Few SeptaAt this early stage, there is minimal scarring and fibrosis, mainly around the portal tracts in the liver. The condition is usually reversible at this point with appropriate treatment and lifestyle changes.Stage 2 (F2): Portal Fibrosis with Occasional SeptaProgressing from the first stage, the liver shows increased fibrosis, with occasional bridging septa formation between the portal tracts. Early intervention is crucial at this stage to prevent further advancement.Stage 3 (F3): Numerous Septa without CirrhosisThe liver now exhibits multiple bridging septa, potentially leading to the distortion of the liver architecture. Timely medical intervention is vital to slow down or halt the progression of liver fibrosis.Stage 4 (F4): CirrhosisIn the final stage of liver fibrosis, extensive scarring and the formation of regenerative nodules disrupt the normal liver structure and function. Cirrhosis can lead to severe complications, and liver transplantation may be the only viable treatment option.Potential Treatments for Liver Fibrosis:1. Lifestyle Changes: Adopting a healthy lifestyle is crucial in managing liver fibrosis. This includes maintaining a balanced diet, exercising regularly, avoiding excessive alcohol consumption, and reducing exposure to toxins.2. Antiviral Therapy: In cases where viral hepatitis is the underlying cause, antiviral medications can help suppress the replication of the virus, reduce inflammation, and slow down fibrosis progression.3. Pharmacological Interventions: Various pharmaceutical agents are being researched for their potential anti-fibrotic effects. These include drugs that target specific signaling pathways involved in fibrogenesis, such as transforming growth factor-beta (TGF-β) inhibitors and angiotensin receptor blockers (ARBs).4. Liver Transplantation: In severe cases of cirrhosis, where liver function is severely compromised, a liver transplant may be the only viable option. However, the availability of suitable donor organs limits the widespread use of this treatment.Conclusion:Liver fibrosis is a complex and progressive condition that can have significant implications for an individual's health. Timely diagnosis, understanding the underlying causes, and implementing appropriate treatments are crucial in managing and potentially halting the progression of this disease. Ongoing research and advancements in medical interventions hold promise for more effective treatments for liver fibrosis in the future.。

基于网络药理学对山楂治疗非酒精性脂肪肝病主要活性成分及潜在靶点分析

基于网络药理学对山楂治疗非酒精性脂肪肝病主要活性成分及潜在靶点分析

1787【实验研究】基于网络药理学对山楂治疗非酒精性脂肪肝病主要活性成分及潜在靶点分析**基金项目:海南省卫健委“省级中医治未病中心能力建设”项目(琼卫中医函〔2019〕9号);国家中医药管理局“全国名老中医药专家传承工作室”建设项目]琼财社(2014)2161号]作者简介:林道斌(1993-),男,海南文昌人,硕士研究生,从 事消化内科的中西医结合临床与研究。

△通讯作者:程亚伟(1982-),女,河南许昌人,副主任医师, 硕士研究生,从事脾胃肝病的中医药临床与研究,Tel : ,E-mail :yaweicheng@ 126. com 。

林道斌,杨华,程亚伟△(海南省中医院脾胃肝病科海口 570000)摘要:目的:运用网络药理学研究方法对山楂治疗非酒精性脂肪性肝病(non-alcoholic fatty liver disease ,NAFLD )主要活性成分及核心靶点进行分析o 方法:采用中药系统药理学分析平台(traditional chinese medicine systems pharmacology database and analysis platform TCMSP )筛选出山楂的有效活性成分及作用靶点蛋白,再使用Unipro 数据库将筛选出的靶点蛋白转换为基因名,通过Gene Cards 数据库、人类孟德尔遗传综合数据库(online mendelian inheritance in man ,OMIM )和治疗靶点、数据库(therapeutic target database ,TTD )收集NAFLD 疾病基因,然后对药物作用基因及疾病相关基因进行vnne 分析,寻找交集靶点,用交集靶点与对 应活性成分构建活性成分-靶点相互作用网络,并进行GO 功能富集分析和KEGG 通路富集分析°结果:研究得到6个作用于NAFLD 疾病靶点的活性成分和148个作用靶点,GO 功能富集分析确定了 350个条目,KEGG 通路分析共发现97条作用通路。

中医药治疗胰腺纤维化的临床对策及研究进展

中医药治疗胰腺纤维化的临床对策及研究进展

·综述·DOI: 10.3969/j.issn.1001-5256.2023.09.034中医药治疗胰腺纤维化的临床对策及研究进展纪晓丹1,龚彪1,李兴佳1,吕婵1,徐莹21 上海中医药大学附属曙光医院消化科,上海 201203;2 上海中医药大学教学实验中心,上海 201203通信作者:徐莹,******************(ORCID: 0000-0002-4645-3094)摘要:胰腺纤维化是慢性胰腺炎疾病发展不可逆的主要病理变化,目前临床针对胰腺纤维化的治疗仍缺乏疗效确切的药物。

本文总结了近年关于中医药治疗胰腺纤维化的临床策略及研究进展。

中医辨证胰腺纤维化涉及到的脏腑有肝、胆、脾、胃;病理因素与火、瘀血、痰湿相关;中药提取物抗胰腺纤维化的相关研究涉及的药物类别包括健脾类、化湿类及化瘀类等,中药方剂治疗胰腺纤维化的相关机制信号通路主要是干预胰腺星状细胞的激活。

以上研究为中医药对胰腺纤维化的预防、干预及防治并发症的深入探索提供了参考。

关键词:胰腺炎,慢性;纤维化;中医药疗法基金项目:国家自然基金青年科学基金项目(82004162);上海市青年科技英才扬帆计划(20yf1449500);上海中医药大学附属曙光医院“四明青年基金”(SGKJ-201924)Application of traditional Chinese medicine in treatment of pancreatic fibrosis:Clinical strategies and research advancesJI Xiaodan1,GONG Biao1,LI Xingjia1,LYU Chan1,XU Ying2.(1. Department of Gastroenterology,Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine,Shanghai 201203,China;2. Teaching and Experiment Center of Shanghai University of Traditional Chinese Medicine, Shanghai 201203, China)Corresponding author: XU Ying,******************(ORCID: 0000-0002-4645-3094)Abstract:Pancreatic fibrosis is the main irreversible pathological change during the progression of chronic pancreatitis, and at present,there is still a lack of effective drugs for the treatment of pancreatic fibrosis in clinical practice. This article summarizes the application of traditional Chinese medicine (TCM) in the treatment of pancreatic fibrosis in recent years from the aspects of clinical strategies and research advances. The TCM syndrome differentiation of pancreatic fibrosis involves the liver,gallbladder,spleen,and stomach,and pathological factors are associated with fire,blood stasis,and phlegm dampness. The research on the anti-pancreatic fibrosis effect of TCM extracts mainly involves spleen-strengthening,dampness-resolving, and blood stasis-resolving drugs, and intervention against the activation of pancreatic stellate cells is the main signaling pathway involved in the mechanism of TCM prescriptions in the treatment of pancreatic fibrosis. The above studies provide a reference for in-depth research on the application of TCM in the prevention and intervention of pancreatic fibrosis and the prevention and treatment of related complications.Key words:Pancreatitis, Chronic; Fibrosis; Traditional Chinese Medicine TherapyResearch funding:National Natural Science Fund for Youth (82004162); Shanghai Young Science and Technology Talents Sailing Program (20yf1449500);“Siming Youth Fund” of Shuguang Hospital affiliated to Shanghai University of Traditional Chinese Medicine (SGKJ-201924)胰腺纤维化是慢性胰腺炎疾病发展的主要病理变化[1],在临床上针对慢性胰腺炎的治疗主要以改善疼痛、预防其急性发作,纠正胰腺内外分泌功能不全及防治并发症为主[2]。

N琥珀酰壳聚糖作为肝脏特异性药物载体

N琥珀酰壳聚糖作为肝脏特异性药物载体

Journal of Controlled Release70(2001)295–307/locate/jconrel Biological characteristics of lactosaminated N-succinyl-chitosanas a liver-specific drug carrier in mice*Yoshinori Kato,Hiraku Onishi,Yoshiharu MachidaDepartment of Drug Delivery Research,Hoshi University,2-4-41Ebara,Shinagawa-ku,Tokyo142-8501,JapanReceived8September2000;accepted4November2000AbstractLactosaminated N-succinyl-chitosan(Lac-Suc)was prepared by reductive amination of N-succinyl-chitosan(Suc)and lactose using sodium cyanoborohydride.Six-day reaction using lactose(12.8-fold(w/w))yielded Lac-Suc with lactosamina-tion degree of30%(mol/sugar unit).Fluorescein thiocarbamyl-Lac-Suc(Lac-Suc-FTC)was prepared by labeling Lac-Suc withfluorescein c-Suc-FTC was injected intravenously at a dose of either1(high dose)or0.2(low dose) mg/mouse.At both doses,Lac-Suc-FTC initially underwent fast hepatic clearance,showed maximum liver localization at8 h,and the amounts localized there were maintained even at48h post-injection.Very slow excretion into feces and urine was observed.The ratio of liver AUC to plasma AUC at low dose was three times higher than that at high dose.On0–48h0–48hthe other hand,the Suc derivative,Gal-Suc,obtained by reductive amination of Suc/galactose showed very little distribution to the liver similarly to Suc itself.Further,since the liver uptake of Lac-Suc-FTC was inhibited by asialofetuin,it was suggested that the liver distribution of Lac-Suc should be concerned with asialoglycoprotein receptor.Thus,Lac-Suc was found available as a carrier exhibiting a high affinity to and long retention in the liver.©2001Elsevier Science B.V.All rights reserved.Keywords:Lactosaminated N-succinyl-chitosan;Distribution;Excretion;Liver-specific drug carrier;Asialoglycoprotein receptor1.Introduction properties[11],and their passive targeting to theliver is also dependent on particle diameter.On the Recently,there have been many studies of liver-other hand,active targeting utilizing receptor recog-targeting systems using methods such as passive nition can be attained using molecules with receptor-trapping of microparticles by reticuloendothelium specific ligands.The biochemical characteristics of [1,2]or active targeting based on hepatic receptor the hepatic asialoglycoprotein receptor,localized on recognition[3–10].The biodisposition characteris-the liver parenchymal cells,have been investigated tics of the microparticles after i.v.administration are in detail[12–16],and this receptor has been utilized influenced extensively by their sizes and surface as a useful site for liver targeting by many re-searchers[3–10].Since the galactose moiety isrecognized specifically by the asialoglycoprotein *Corresponding author.Tel.:181-3-5498-5760;fax:181-3-receptor,macromolecules used as carriers for macro-5498-5759.E-mail address:d711@hoshi.ac.jp(Y.Kato).molecule–drug conjugates have often had a galactose0168-3659/01/$–see front matter©2001Elsevier Science B.V.All rights reserved.PII:S0168-3659(00)00356-4296Y.Kato et al./Journal of Controlled Release70(2001)295–307moiety added,and the products have been examined(averaged);degree of N-succinylation0.81mol/for their usefulness as liver-specific drug carriers.sugar unit;degree of deacetylation 1.0mol/sugar For example,when galactose moieties were intro-unit)was kindly donated by Katakura Chikkarin duced into serum albumin[3,4],N-(2-hydroxy-(Tokyo,Japan).b-Lactose(lactose),b-galactose propyl)methacrylamide copolymer[5,7],asialofetuin(galactose),fluorescein isothiocyanate(FITC), [6]and poly-L-glutamic acid[8],the products asialofetuin(type I),collagenase(type VIII),bovine functioned well as liver-specific drug carriers.serum albumin(fraction V),and HEPES buffer(1 N-Succinyl-chitosan(Suc)has been demonstrated M)were purchased from Sigma Chemical Company to be highly safe[17,18]and to be available as a(St.Louis,USA).Hanks’Balanced Salt Solution was macromolecular drug carrier showing very long-term purchased from Life Technologies(MD,USA). retention in the systemic circulation[19,20].This Sodium cyanoborohydride was purchased from long-term retention is based on the low biodeg-Tokyo Kasei Kogyo(Tokyo,Japan).All reagents radability as well as high molecular weight,and thus were of the highest grade available.Suc is available for passive targeting to disease Suc(100mg)was dissolved in3ml of1/15M regions with the highly vascular permeation[19,20].phosphate buffer(pH6.0)with stirring,and then3 This property is also very useful for active targeting ml of methanol were added.To the solution was from the systemic circulation to the target site based added lactose(1280mg)dissolved in1ml of the on receptor recognition of ligands because the long-same buffer.After stirring,sodium cyanoborohydride term circulation allows prolonged supply of conju-(320mg)dissolved in1ml of the same buffer was gated drugs to the target site.Furthermore,when Suc added to the solution,followed by stirring at400 is trapped by the target site cells,it is considered to rev./min at room temperature for6days.After the remain longer in them due to low biodegradability;reaction,methanol was removed from the mixture on the long retention in the target cells is supposed to be a rotary evaporator under reduced pressure with responsible for the good action of Suc–drug conju-slight warming in a water bath,and then separated®gates.Such long retention effect may not be on a Sephadex G-50column(3.5cm in inner achieved in the case of proteins or synthetic poly-diameter310.5cm in length)using1/15M phos-peptides that are degraded relatively quickly.There-phate buffer as an elution solvent.The eluted solu-fore,Suc is an attractive macromolecule for receptor tion at the high molecular weight fractions were targeting from the systemic circulation to the target gathered and dialyzed for3days against water using site.Suc possesses many functional groups such as Seamless Cellulose Tubing(molecular weight cut off carboxyl groups and amino groups,which are con-limit512,000–14,000;Viskase sales Corp.,USA). sidered to facilitate the introduction of galactose Finally,lactosaminated Suc(Lac-Suc)was obtained moieties.In this study,the introduction of lactose to by lyophilization of the dialyzed solution.The Suc by reductive amination was attempted.The content of lactose residues in Lac-Suc was examined product,lactosaminated Suc(Lac-Suc),was labeled by elemental analysis(Yanako Analytical Industrial, withfluorescein isothiocyanate(FITC)and the phar-Japan)after extensive drying at808C in a desiccatormacokinetics,i.e.biodistribution,elimination and with P O for3h.The degree of lactose in Lac-Suc25excretion,of the labeled Lac-Suc(Lac-Suc-FTC)could be calculated from the C/N ratio in elemental were examined in mice.Furthermore,the specific analysis as0.30mol/sugar unit.binding of Lac-Suc to the asialoglycoprotein receptor Fluorescein thiocarbamyl(FTC)-Lac-Suc,ab-of the liver was examined by the competitive binding breviated to Lac-Suc-FTC,was prepared to monitor study with asialofetuin.Suc in the body as follows:FITC(4mg)dissolvedin4ml of0.5M carbonate buffer(pH8.94)wasadded to Lac-Suc(100mg)in10ml of the same 2.Materials and methods buffer,and the mixture was stirred at room tempera-ture in the dark for20h.The product,c-Suc-®2.1.Materials FTC was purified by gel-filtration with a SephadexG-50column(3.2cm in inner diameter310.5cm in5N-Succinyl-chitosan sodium salt(Suc:M3310length)using0.5M carbonate buffer as the elutionwY.Kato et al./Journal of Controlled Release70(2001)295–307297 solvent and subsequent dialysis against water.Final-samples were withdrawn and several tissues(liver, ly,Lac-Suc-FTC was obtained as powder after kidney,spleen and lung)were excised.Each organ lyophilization.The FTC content of Lac-Suc-FTC except the blood was washed with PBS,gently was calculated from the absorbance at495nm using blotted usingfilter paper and weighed.A threefold®a DU640spectrophotometer(Beckman,USA)in volume of PBS was added,and the mixture was phosphate buffered saline,pH7.4,(PBS)based on homogenized using a glass homogenizer with a the absorbance of FITC at495nm in the same Teflon pestle.The supernatant was obtained by buffer.The profiles forfluorescence quenching of centrifugation(3000rev./min,10min).Plasma was Lac-Suc-FTC in aqueous solution or biological obtained by centrifugation of the blood.The superna-media were checked during the incubation period.tant and plasma were diluted appropriately with PBS, The Lac-Suc-FTC solutions of1and0.2mg dis-and theirfluorescence intensities were investigated solved in0.2ml of PBS were put into the glass tubes(Ex5495nm,Em5520nm).The blank sample was shielded from the light,which included1ml of PBS obtained by injecting normal saline alone into mice or of20%(v/v)plasma in PBS,and the mixtures instead of Lac-Suc-FTC solution;blood and tissues were incubated at378C at60rev./min.not containing Lac-Suc-FTC were taken from themice and treated in the same way.The diluted 2.2.Animals supernatant and plasma were measuredfluorometri-cally under the conditions described above.The Male C57BL/6mice(6weeks old,specific patho-concentration of Lac-Suc-FTC in the sample was gen-free)weighing around20g were purchased from determined from the netfluorescence intensity ob-Tokyo Laboratory Animals Science(Tokyo,Japan).tained by subtracting thefluorescence intensity of the The experimental protocol was approved by the blank from that of each sample based on the standard Ethics Review Committee for Animal Experimenta-calibration curve.The concentration was corrected tion of Hoshi University.These animals were kept by the recoveries stated earlier.The distributed on the breeding diet MF(Oriented Yeast,Tokyo)amount was calculated from the concentration and with water ad libitum in a room maintained at tissue weight.23618C and a relative humidity of6065%.Theywere used soon after purchase.Three animals wereused in each point on experiments except for the 2.4.Pharmacokinetic analysisrecovery ratios of Lac-Suc-FTC from tissue homoge-nate and plasma.In the initial phase(0–1h post injection),theelimination rate constant(k)for the plasma con-P2.3.Body distribution studies centration was estimated from the slope of the best-fitted mono-exponential decline curve,the distribu-The body distribution of Lac-Suc-FTC was in-tion volume(V)was by dividing the dose by thedvestigated after administration of Lac-Suc-FTC dis-concentration estimated at time50,and the plasmaPsolved in normal saline at a dose of1or0.2mg per clearance(CL)was given by V3k.The aread P mouse.The recoveries of Lac-Suc-FTC from each under the plasma concentration–time curve for0–t hPtissue homogenate and plasma were determined in(AUC),the area under the liver concentration–0–t hLadvance as reported previously[20].The recoveries time curve for0–t h(AUC),the mean residence0–t hof Lac-Suc-FTC from each tissue homogenate and time given by the plasma concentration–time curvePplasma were obtained as the mean of two experi-for0–t h(MRT)and the mean residence time0–t hments as follows:108%(liver),87%(spleen),90%given by the liver concentration–time curve for0–tL(kidney),77%(lung),130%(feces)and105%h(MRT)were calculated using the trapezoidal0–t h(plasma);the difference of the individual data was method.Further,as to the liver,average hepaticLvery little.Normal mice received Lac-Suc-FTC via clearance for0–t h(CL)was estimated by0–t hthe lateral tail vein at a dose of1or0.2mg(0.2ml)dividing the amount located in the liver at time tt Pwithout anesthetization.The mice were sacrificed at(X)by AUC as shown in the following equa-L0–t h5min,0.5,1,8,24and48h after injection,blood tion:298Y.Kato et al./Journal of Controlled Release70(2001)295–307L t PCL5X/AUC.(1)breviated as Suc-FTC and Gal-Suc-FTC,respective-0–t h L0–t hly.Normal mice received Suc-FTC or Gal-Suc-FTCThe initial liver uptake rate(v)was determined via the lateral tail vein at a dose of0.2mg(0.2ml)Lfrom the slope of the initial hepatic accumulation.with no anesthetization,and were kept separately in Concerning the hepatic clearance stated above,the metabolite cages immediately after administration. outflow from the liver was assumed to be negligible The mice were sacrificed at8h after injection,blood at early time points judging from general hepatic samples were collected and several tissues(liver, uptake kinetics based on asialoglycoprotein[14–16].kidney,spleen and lung)were removed.Further-The elimination rate from the liver(k)was analyzed more,urine and feces were collected for8h afterLby assuming a terminal decrease following a mono-administration,and then urinary volume and fecal exponential decline.The half-lives in the plasma weight were measured.The following procedures were calculated as0.693/(elimination rate constant).and measurements were performed in the same wayas described in the body distribution studies and 2.5.Urinary and fecal excretion studies urinary and fecal excretion studies.Cumulative collection of urine and feces was petitive liver uptakeperformed simultaneously in the biodistributionstudies as described above.Animals were kept In vivo accumulation to the liver:Lac-Suc-FTC separately in metabolite cages immediately after and asialofetuin[21,22]in saline were co-adminis-administration.Urine and feces were collected for8,tered intravenously to ly,the dose of 24and48h after i.v.administration,and then asialofetuin was0,0.1,1and10mg per mouse, urinary volume and fecal weight were measured.while Lac-Suc-FTC was injected at a constant dose Each urine sample wasfiltered using a membrane of0.1mg per mouse.At appropriate time after filter(0.45m m pore diameter).A ninefold volume of injection,the mice were sacrificed,blood samples PBS was added to feces,and the mixture was were collected and liver was enucleated.The con-ultrasonicated at28kHz for40min.The supernatant centration of Lac-Suc-FTC in the plasma and liver was obtained by centrifugation(3000rev./min,10was determined in the same manner as described in min).The supernatant and urinefiltrate were diluted Section2.3.appropriately with PBS,and theirfluorescence inten-Liver perfusion studies:Lac-Suc-FTC and asialo-sities were measuredfluorometrically(Ex5495nm,fetuin in saline were co-administered intravenously Em5520nm).After the blank test,the concentration to mice in the same manner as described above.At of Lac-Suc-FTC was measured from the netfluores-60min after administration,mice were laparotom-cence intensity using a calibration curve in the same ized,and the portal vein,vena cava and aorta were manner as in the distribution study.The total cut.The liver was perfused with PBS through vena amounts excreted in urine and feces were calculated cava and aorta for8min and then with0.1M from the concentration and urinary volume or fecal HEPES buffer containing collagenase at0.05%(w/ weight.v)for8min.The perfusion rate was kept at3–4ml/min.After the perfusion wasfinished,the liver parison of biodistributions of was removed from the mice.As to the isolation of lactosaminated N-succinyl-chitosan(Lac-Suc),N-liver cells,the method by Nilsson and Berg[23]was succinyl-chitosan(Suc)and galactosaminated N-modified and adapted.Briefly,the cells were sus-succinyl-chitosan(Gal-Suc)pended in20ml of0.1M Hanks’-HEPES buffercontaining0.1%BSA,referred to hereafter as H-H Galactosaminated Suc(Gal-Suc)was also syn-buffer,by gentle stirring at48C overnight.The initial thesized in the same manner as Lac-Suc,i.e.reduc-cell suspension wasfiltered through four layers of tive amination,except using galactose instead of gauze(Nishio eizai Co.,Ltd.,Japan).The cell lactose.Suc and Gal-Suc were reacted with FITC to number was counted by microscopy(Olympus obtain FTC moiety-carrying Suc and Gal-Suc,ab-BX50F,Japan).The cell suspension was then cen-Y.Kato et al./Journal of Controlled Release70(2001)295–307299 trifuged at500rev./min for2min.The supernatant,obtain the distributed concentration in PC and NPC containing most of the non-parenchymal cells of the initial liver.(NPC),wasfirst centrifuged further for2min at500rev./min to remove parenchymal cells(PC).Cells 2.8.Statistical analysisremaining in the supernatant were then centrifuged at1750rev./min for3min.The pellet was resuspended Student’s t-test was used to determine significant in H-H buffer and washed by centrifugation for3difference.Differences were considered significant min at1750rev./min.The pellet was resuspended in when the P value was less than0.05.H-H buffer and was again centrifuged at500rev./min for2min.The supernatant was sedimented at1750rev./min for3min,and the pellet(NPC)was3.Resultsfinally resuspended in3ml of PBS.On the otherhand,thefirst pellet containing most of PC waswashed twice by centrifugation at500rev./min for2 3.1.Body distribution offluorescein thiocarbamyl-min.The pellet(PC)wasfinally resuspended in3ml lactosaminated N-succinyl-chitosan(Lac-Suc-FTC) of PBS.The cell number infinal suspension of PC orNPC was again counted by microscopy,and the The synthetic approach of Lac-Suc is illustrated in recovery ratio of cell number was calculated from Fig. ctose is a disaccharide that consists of those before and after isolation.Eachfinal cell galactose and glucose.Amino groups of Suc were suspension was homogenized,and the concentration combined with an aldehyde group of the glucose of Lac-Suc-FTC in the suspension was determined moiety of lactose,and the Schiff bases formed were fluorometrically as described in Section 2.3.The reduced by cyanoborohydride into secondary amino concentration of Lac-Suc-FTC in the sample was groups[24],which meant that the glucose moiety corrected by the recovery ratio of cell number to was changed into another structure.Therefore,asFig.1.Synthetic scheme of lactosaminated N-succinyl-chitosan(Lac-Suc).300Y.Kato et al./Journal of Controlled Release70(2001)295–307shown in Fig.1,only the structure of galactose percentage of dose in plasma or each tissue.The remained intact.elimination from plasma occurred much faster com-The long exposure offluorescent molecules in pared with that reported previously for Suc-FTC solution results in the possibility of quenching.[20].Namely,Lac-Suc-FTC had almost completely Therefore,elucidation of this property was consid-disappeared from blood circulation at24h after ered necessary for quantification based on the injection,while Suc-FTC was retained at34%of fluorescent moiety.Thefluorescence intensity of dose in plasma at24h post-injection.The dis-Lac-Suc-FTC in PBS alone was quenched to around tribution of Lac-Suc-FTC in the liver rapidly reached 90%after24h incubation and to around80%after approximately12.6%(w/w)of the dose at1h 48h.However,in20%(v/v)plasma,no quenching post-injection,and reached the maximum of16.6% was observed after24h incubation,and quenching(w/w)of the dose at8h c-Suc-FTC was seen very little even after48h incubation(data was sustained in the liver at a similar high level,and not shown).From these results,the quenching effect14.0%(w/w)of the dose remained even at48h was considered to be negligible for in vivo quantita-post-injection.On the other hand,Lac-Suc-FTC was tive analysis of biodistributed Lac-Suc-FTC in this present at very low levels or not at all in other tissues experiment.The bond between Lac-Suc andfluores-throughout the experimental period.cein moiety was considered to be stable in the body Fig.2B shows the time course of changes in body by referring to the previous results[19].Namely,distribution of Lac-Suc-FTC after i.v.administration when Suc-FTC was administered into mice,only at a dose of0.2mg per mouse.The results are Suc-FTC was observed in urine and plasma but no expressed as the percentage of dose in plasma or freefluorescein was detected there;further,since each c-Suc-FTC was eliminated almost freefluorescein itself was quite susceptible to urinary completely from plasma within8h post-injection. excretion,non-detection of freefluorescein suggested The amount of Lac-Suc-FTC distributed in the liver that its liberation should not be caused[19].There-rapidly increased and reached22.3%(w/w)of dose fore,liberation of freefluorescein from Suc-FTC was at1h post-injection,and reached the maximum of considered to be negligible in the body.Similarly,23.0%(w/w)of dose at8h after injection.The level Lac-Suc-FTC obtained in the same labeling method of Lac-Suc-FTC in the liver was then gradually was considered not to relievefluorescein in the body.reduced to10.4%(w/w)of dose at48h post-Fig.2A shows the time course of biodistribution injection.The amounts in other tissues were very of Lac-Suc-FTC after i.v.administration at a dose of low.Thus,the elimination rate from plasma was 1mg per mouse.The results were expressed as the more rapid at0.2mg than at1mg per mouse,andFig.2.Plasma concentration and tissue distribution of Lac-Suc-FTC after i.v.administration at a dose of1mg(A)or0.2mg(B)(0.2ml) per normal mouse(20g).h,Plasma;d,liver;n,kidney;3,lung;ȣ,spleen.Each point represents the mean6S.D.(n53).Y.Kato et al./Journal of Controlled Release70(2001)295–307301Fig.3.Pharmacokinetic profiles of Lac-Suc-FTC in the plasma and liver after i.v.administration at a dose of0.2mg or1mg per normal mouse(20g).(A)Plasma concentration after injection;(B)accumulated amount in the liver per mouse after injection;(C)accumulated L P amount(X)in the liver per mouse at time t after injection vs.area under the plasma concentration–time curve for0–t h(AUC)per t0–t hmouse.3,3,---,1mg;h,h,———,0.2mg.The broken lines are the linear curves best-fitted in the initial phase(0–1h).the ratio of Lac-Suc-FTC distributed in the liver to cated that elimination from the plasma was non-the dose was higher at0.2mg than at1mg per linear.During the initial1h after injection,the mouse.However,as to elimination from the liver,amount accumulated in the liver increased approxi-Lac-Suc-FTC underwent faster reduction at0.2mg mately linearly with time(Fig.3B).The initialthan at1mg per mouse.As to the sensitivity in this uptake rates(v)by the liver were110and42m g/hLfluorometrical analysis,for example,it was possible per mouse,that is1.9and0.70m g/min per mouse,at to detect the concentration of at least0.2m g/ml or g the doses of1and0.2mg per mouse,respectively.P for plasma and liver,indicating sensitivity of less Fig.3C shows the relationship between the AUC0–t hLthan0.1%of dose/ml or g at the dose of0.2mg per value and the amount(X)accumulated in the livertmouse in them.at time t.The average hepatic uptake clearancesL(CL)for the initial0–1h were calculated as0–1h3.2.Pharmacokinetic analysis0.12and0.33ml/h per mouse at doses of1and0.2mg per mouse,respectively,using Eq.(1).TheseLFig.3A shows the semi-logarithmic plots of CL values were around one third and a half of0–1hPplasma concentration of Lac-Suc-FTC.Approxima-the CL values at doses of1and0.2mg per0–1htion tofirst-order decrease kinetics provided elimina-mouse,respectively.These kinetic parameters for the21tion rate constants(k)of0.43and0.54h at doses plasma clearance and hepatic clearance for0–1h are Pof1and0.2mg per mouse,respectively.The summarized in Table1.distribution volumes(V),obtained from the dose The moment values in a long scale(0–48h)for dand calculated initial plasma concentration in Fig.the plasma and liver were compared between the 3A,were not markedly different between the two doses of1and0.2mg per mouse(Table2).TheP Pdoses.The initial plasma clearances(CL)indi-AUC values of Lac-Suc-FTC at doses of1and0–1h0–48hTable1a Pharmacokinetic parameters of Lac-Suc-FTC for plasma clearance and hepatic uptake in the initial phase(0–1h)in normal miceP P L Lac-Suc-FTC k t V CL v CL P1/2d0–1h L0–1h(1/h)(h)(ml)(ml/h)(m g/h)(ml/h) 1mg0.43 1.60.780.341100.120.2mg0.54 1.3 1.10.60420.33a P LV,CL,v and CL are expressed as the values per normal mouse.d0–1h L0–1h302Y.Kato et al./Journal of Controlled Release70(2001)295–307Table2Pharmacokinetic parameters of Lac-Suc-FTC for long term biodistribution and hepatic elimination in the latter phase(8–48h)in normal amiceP P L L L LLac-Suc-FTC AUC MRT AUC MRT AUC CL k 0–48h0–48h0–48h0–48h0–48h0–48h L (h?m g/ml)(h)(h?m g/ml)(h)(ml/h)(1/h)PAUC0–48h1mg7300 4.4770024 1.10.020.0050.2mg500 1.5190019 3.40.040.025a P L LAUC,AUC,CL are expressed as the values per normal mouse.0–48h0–48h0–48h320.2mg per mouse were about7.3310and5.5310excreted Lac-Suc-FTC.Therefore,urine collectionPh?m g/ml,respectively.Also,the MRT of Lac-was performed over longer time intervals of8,240–48hSuc-FTC at doses of1and0.2mg per mouse were and48h after injection.The urine stored in the cage approximately 4.4and 1.5h,respectively.The bottle and that withdrawn from the bladder were L LAUC and MRT of Lac-Suc-FTC at a dose combined to obtain the total urine excreted.The 0–48h0–48h3of1mg were calculated to be about7.7310h?m g/level of excretion increased gradually in both urineLml and 2.4h,respectively.The AUC and and feces.The urinary and fecal excretion rates0–48hLMRT of Lac-Suc-FTC at a dose of0.2mg were tended to be faster at a dose of0.2mg than1mg.0–48h3calculated to be about1.9310h?m g/ml and19h,However,the percentages of dose excreted did notPrespectively.Thus,the AUC of Lac-Suc-FTC show significant differences between urine and feces0–48h(1mg per mouse)was about13times larger than that(P.0.05).of Lac-Suc-FTC(0.2mg per mouse),while theLAUC of Lac-Suc-FTC(1mg per mouse)was0–48habout four times greater than that of Lac-Suc-FTC parison of biodistribution amongL(0.2mg per mouse).That is,the ratios of AUC lactosaminated N-succinyl-chitosan(Lac-Suc),N-0–48hPto AUC were1.1and3.4at doses of1and0.2succinyl-chitosan(Suc)and galactosaminated N-0–48hmg per mouse,respectively.The very slow elimina-succinyl-chitosan(Gal-Suc)tion of Lac-Suc-FTC from the liver was observed ateach dose.Suc-FTC and Gal-Suc-FTC were investigated forbiodisposition at8h after i.v.injection at a dose of 3.3.Urinary and fecal excretion0.2mg per mouse.The results are shown in Fig.4.As expected,Suc-FTC exhibited a high distribution Urinary and fecal excretion are shown in Table3.in the systemic circulation and was scarcely distrib-The urinary volume collected until1h after i.v.uted to the liver,where the distributed amount was injection was too small to determine the amount of significantly lower than that of Lac-Suc-FTC(P,0.001).Most of the injected Gal-Suc-FTC waseliminated from the plasma at8h after injection,and Table3it showed little distribution in the tissues tested,urine Urinary and fecal excretion of Lac-Suc-FTC at8,24,and48h or feces.The amount of Gal-Suc-FTC distributed toaafter i.v.administration in normal mice the liver was significantly lower than that of Lac-Lac-Suc-FTC Excretion(%of dose)Suc-FTC(P,0.001).Thus,Gal-Suc-FTC was sug-8h24h48h gested to be distributed to tissues other than thosetested in this study.Further studies are therefore 1mg Feces0.1360.090.760.2 2.760.8required to determine the tissue distribution of Gal-Urine 1.160.6 1.861.0 3.360.90.2mg Feces0.0960.05 1.760.8 5.062.1Suc-FTC.These results of the present study demon-Urine 1.260.7 2.861.7 6.363.5strated that Lac-Suc-FTC was superior as a drug a Each value represents the mean6S.D.(n53).carrier for liver targeting.。

疏风解毒胶囊治疗肝经郁热型带状疱疹的临床疗效观察

疏风解毒胶囊治疗肝经郁热型带状疱疹的临床疗效观察

World Latest Medicne Information (Electronic Version) 2017 Vo1.17 No.582·中医中药·疏风解毒胶囊治疗肝经郁热型带状疱疹的临床疗效观察范兴立,禹辉,王江潮(黄河三门峡医院 皮肤科,河南 三门峡 472000)0 引言带状疱疹是皮肤科常见疾病之一,在机体免疫力下降时,潜伏在神经节的水痘-带状疱疹病毒(VZV)引起的一种急性疱疹性皮肤病。

因皮损状如蛇行,中医称之为“蛇串疮”;因每多缠腰而发,故又称“缠腰火丹”;本病又称之为火带疮、蛇丹、蜘蛛疮等。

常表现为皮肤上出现带状分布的红斑、水疱等,沿一侧的周围神经分布,局部或伴刺痛感。

我院皮肤科门诊于2015年4月至2016年2月期间,采用口服疏风解毒胶囊联合口服泛昔洛韦、肌注维生素B12、红光照射治疗带状疱疹取得了满意的疗效。

观察结果报道如下:1 资料与方法1.1 一般资料。

全部病例均来自2015年4月至2016年2月期间黄河三门峡医院皮肤科门诊,共观察78例,参照《中国临床皮肤病学》[1]及《中医外科学》[2],符合带状疱疹的西医诊断标准和肝经郁热型的中医证候标准,病程均在一周之内,未服用及外用抗病毒药物,无肝、肾疾病,无过敏史,非妊娠、哺乳期患者等。

按就诊顺序随机分为治疗组39例,男20例,女19例,年龄在34~70岁,平均(51.2±20.1)岁;对照组39例,男17例,女22例,年龄在37~71岁,平均(52.3±19.6)。

两组经统计学分析,在性别、年龄、病程、皮损严重程度、中医证候等方面没有显著性差异(P>0.05),有可比性。

1.2 治疗方法。

治疗组:采用口服疏风解毒胶囊(安徽济人药业有限公司 国药准字Z20090047 规格0.52g)口服,每次4粒,每天3次,同时配合泛昔洛韦胶囊口服,每次0.25g,每天3次,肌注维生素B12注射液0.5mg,每天1次,皮损处局部照射红光,每次20min,每天1次。

肝病常用英文

肝病常用英文

【原创】一起学习肝病专业英语词汇肝硬化并发症:The complications of liver cirrhosis 核苷类似物:Nucleoside analogues Nucleoside analogs乙肝肝硬化:Hepatitis B cirrhosis 肾功能:renal function肾小球滤过率(GFR ,glomerular filtration rate)指南:guide 亚肝会指南APASL guide 慢加急性肝衰竭:Acute-On-Chronic Liver Failure 长期:over a long period of time;long-term Hemochromatosis :血色沉着病Phlebotomy :放血, 静脉切开放血术Copper Chelator :铜螯合剂Penicillamine :青霉胺Alpha-1 antitrypsin deficiency alpha-1 :抗胰蛋白酶缺陷症Ribavirin :三(氮)唑核苷,病毒唑(抗病毒药)Deferoxamine :去铁胺Pruritus :搔痒症Osteoprosis :骨质疏松症Scleroderma :硬皮病gallbladder distention 胆胀hypochondriac pain[disease] 胁痛[ 病] hepatic insufficiency 肝衰竭hepatic lobule 肝小叶hepatic tumor 肝瘤hepaptosis 肝下垂heparinization 肝素化heparinocyte 肝素细胞hepatalgia 肝痛hepatargia 肝衰竭hepatatrophia 肝萎缩hepatectomy 肝切除术hepatic amebiasis 肝阿米巴病hepatic bile 肝胆汁hepatic cell 肝细胞hepatic cirrhosis 肝硬变hepatic coma 肝性昏迷hepatic cords 肝细胞索hepatic echography肝回波描记术hepatic failure 肝衰竭hepatic fetor 肝病性口臭hepatic insufficiency肝衰竭肝十二指肠吻合术肝小肠吻合术 肝管胃吻合术 肝管空肠吻合术肝样变 肝胚细胞瘤肝癌肝细胞癌肝细胞性黄疸肝脑综合征肝管十二指肠吻合术 肝管肠吻合术 肝管胃吻合术hepatic lobule肝小叶 hepatic tumor 肝瘤 hepatico duodenostomyhepatico enterostomyhepatico gastrostomyhepaticojejunostomyhepaticotomy 肝管切开术hepatitis virus 肝炎病毒hepatization hepatoblastoma hepatocarcinoma hepatocele 肝突出 hepatocellular carcinoma hepatocellularjaundice hepatocerebralsyndrome hepatocholangioduodenostomy hepatocholangioenterostomyhepatocholangiogastrostomy hepatocholangiostomy 胆管造口术hepatocirrhosis 肝硬变 hepatocyte 肝细胞 hepatodynia 肝痛hepatogenous diabetes 肝原性糖尿病hepatogram 肝搏动图hepatography 肝x 线照相术hepatolenticular degeneration 肝豆状核变性hepatolith 肝石hepatolithectomy 肝石切除术hepatolithiasis 肝石病hepatology 肝脏病学hepatoma 肝细胞瘤hepatomegalia 肝大hepatomegaly 肝大hepatomelanosis 肝黑变病hepatomphalocele 脐部肝突出hepatomphalos 脐部肝突出hepatonephritis 肝肾炎hepatopexy 肝固定术hepatorenal syndrome 肝肾综合征hepatorrhagia 肝出血hepatorrhaphy 肝缝术hepatorrhea 肝液溢hepatorrhexis 肝破裂hepatoscintigram 肝闪烁图hepatoscopy 肝检查hepatosis 肝机能障碍hepatosplenography 肝脾x 线照相术hepatosplenomegaly 肝脾大hepatotherapy 肝剂疗法hepatotomy 肝切开术hepatotoxemia 肝性毒血病hepatotoxicity 肝毒性BILIRUBIN - Chemical breakdown product of hemoglobin. Measured specimen by laboratory to assess function of liver.胆红素——血色素化学损坏的产物。

新抗癌药隐忍物力达霉素的转换辅基蛋白对肿瘤组织细胞的结合作用

新抗癌药物力达霉素的辅基蛋白对肿瘤组织细胞的结合作用Ƞ王健康ȱȠȠ孟茹松ȲȠ 李忠东ȲȪȠ(1.中国医学科学院医药生物技术研究所ȠȠȲȮȠ空军总医院ȠȠȠȠȠȱȰȰȰȳȶ)ȠȠ据夏俊峰家属透露,夏俊峰在庭审中称,自己先被踢了一脚,后又被打了下身,弯下腰时摸到口袋里的小刀,划拉了几下自己也不知道。

辩护律师认为,该案的起因是2009年5月16日沈河区城管申凯、张旭东等十几人进行野蛮执法。

夏俊峰不属于故意杀人,其行为符合正当防卫的条件。

ȠȠ2009年11月15日,沈阳市中级人民法院一审判决,认定夏俊峰的行为构成故意杀人罪,判其死刑,剥夺政治权利终身。

ȠȠ法院认为,被告人夏俊峰在与城管执法人员因摆摊占道问题发生争执后,持刀在被害人办公室行凶,造成2人死亡、1人受重伤。

其犯罪手段特别残忍,情节极其恶劣,后果极其严重,应依法严惩。

遂作出上述判决。

编辑本段终审判决ȠȠ2011年5月9日上午,沈阳小贩夏俊峰刺死城管案终审宣判,辽宁省高级法院作出刑事裁定,驳回上诉,维持原判:夏俊峰因故意杀人罪,判处死刑。

ȠȠ夏俊峰称,自己在勤务室被申凯、孙旭东两名城管队员殴打,一时激怒拿刀乱刺。

但辽宁省高院认为,没有足够证据表明夏俊峰“遭到了明显的、危及人身安全的不法侵害行为。

ʔȠȠ且由于目击证人被禁止进入法庭,夏俊峰的自卫杀人一说成为孤证,终审法庭未予采纳。

ȠȠ摘要: 背景与目的Ƞ力达霉素是由一个辅基蛋白质和一个发色团组成的烯二炔类抗肿瘤抗生素,在体外对肿瘤细胞显示出极强的杀伤作用。

其发色团对肿瘤细胞有杀伤作用,而其辅基蛋白对发色团有保护和稳定作用,但辅基蛋白对肿瘤细胞是否有结合作用,目前尚未见报导。

本实验研究力达霉素辅基蛋白(ɌɄɐ)对肿瘤细胞是否有结合作用,并考察这种结合作用与肿瘤生物学行为的相关性。

方法 用异硫氰酸荧光素酯(ɆɉɔɃ)与ɌɄɐ进行偶联,以此偶联物与临床常见的肺癌、胃癌、胰腺癌、直肠癌和乳腺癌组织标本在一定条件下孵育,通过荧光显微镜观察荧光染色情况,按荧光强弱程度将着色结果分成阳性、可疑、阴性ȳ级。

NAFLD

非酒精性脂肪性肝病诊疗指南(2010年1月修订)全网发布:2015-11-05 22:39 发表者:尹有宽6185人已访问中华医学会肝脏病学分会脂肪肝和酒精性肝病学组非酒精性脂肪性肝病(nonalcoholic htty liver disease,NAFI.D)是一种与胰岛素抵(insulinresistance,IR)和遗传易感密切相关的代谢应激性肝脏损伤,其病理学改变与酒精性肝病(alcoholic liver diseaseALD)相似,但患者无过量饮酒史,疾病谱包括非酒精性单纯性脂肪肝(nonalcoholicsimple faay liVet,NAFL)、非酒精性脂肪性肝炎(nonalcoholicsteatohepatitis,NASH)及其相关肝硬化和肝细胞癌【1-2】。

NAFLD是2l世纪全球重要的公共健康问题之一,亦是我国愈来愈重要的慢性肝病问题【3】。

为进一步规NAFLD的诊断和治疗,中华医学会肝脏病学分会脂肪肝和酒精性肝病学组组织有关专家,在参考国内外最新研究成果和相关诊疗共识的基础上【4-9】,按照循证医学的原则,对2006年制定的《非酒精性脂肪性病疗指南》【l0】刮进行更新。

其中推荐的意见所依据的证据等级共分为3个级别5个等次【11】,中分别以括号内罗马数字和阿拉伯数字表示。

本指南只是帮助医师对NAFID的诊治做出正确决策,不是强制性标准,也不可能包括或解决NAFLD诊疗中的所有问题。

临床医师在针对某一具体患者时,应充分了解本病的最佳临床证据和现有医疗资源,并在全面考虑患者具体病情及其意愿的基础上,根据自己的知识和经验,制定合理的诊疗方案。

由于NAFLD的研究进展迅速,本指南仍将根据学科进展和临床需要不断更新和完善。

一、流行病学NAFLD是欧美等西方发达国家肝功能酶学异常和慢性肝病最常见的原因,普通成人NAFLD 患病率为20%一33%,其中NASH及其相关肝硬化分别占lO%一20%和2%~3%【l-2,12】。

减轻肝脏负担得英文作文

减轻肝脏负担得英文作文Reducing the Burden on the Liver。

The liver is one of the most important organs in our body. It plays a vital role in detoxifying the blood, producing bile, and storing glucose. However, due to our modern lifestyle and diet, the liver is often overworked and can become damaged over time. Therefore, it isessential to take steps to reduce the burden on the liver and keep it healthy.One of the most important things we can do to reduce the burden on the liver is to maintain a healthy diet. This means avoiding processed foods, sugary drinks, and excessive amounts of alcohol. Instead, we should focus on eating a diet rich in fruits, vegetables, whole grains, and lean proteins. These foods provide the nutrients our liver needs to function properly and help to prevent damage from occurring.Another way to reduce the burden on the liver is to exercise regularly. Exercise helps to improve blood flowand oxygenation throughout the body, including the liver. This can help to improve liver function and reduce the risk of liver damage. Additionally, exercise can help to reduce stress, which is another factor that can contribute toliver damage.In addition to diet and exercise, there are severalother things we can do to reduce the burden on the liver. For example, we can avoid exposure to toxins and pollutants, such as cigarette smoke and chemicals in cleaning products. We can also take steps to manage chronic conditions, suchas diabetes and high blood pressure, which can increase the risk of liver damage.Overall, reducing the burden on the liver is essential for maintaining good health. By eating a healthy diet, exercising regularly, and avoiding toxins and pollutants,we can help to keep our liver functioning properly and prevent damage from occurring. If you are concerned aboutyour liver health, be sure to talk to your doctor for more information and guidance.。

鸡腿菇复合制剂对小鼠肝脏的保护作用

鸡腿菇复合制剂对小鼠肝脏的保护作用刘芹;耿雪冉;许瀛引;柳万石;王贺祥【摘要】The hepatoprotective potential of Coprinus comatus‐compoundis discussed in vivo using a hepatotoxicity model of CCl4‐induced liver injury . Neutralization of CCl4‐induced hepatotoxicity by Coprinus comatus‐compound is evaluated in mice . Towards this ,serum levels of hepatic injury markers (glutamic‐oxaloacetic transaminase and glutamic‐pyruvic transaminase) , malondialdehyde and antioxidant enzymes (superoxide dismutase and glutathione peroxidase ) in the liver homogenates , and histological examination are performed . The results show that administration of Coprinus comatus‐compound can significantly prevente the elevation in serum glutamic‐oxaloacetic transaminase (GOT ) and glutamic‐pyruvic transa minase (GPT ) activities in acute liver damage induced by CCl4 and suppressed hepatic malondialdehyde(MDA) formation . Mice treated with Cop rinus comatus‐compound is demonstrated a better profile of antioxidants with augmented activities of superoxide dis mutase (SOD) and glutathione peroxidase (GSH‐PX ) in the liver .&nbsp;The results indicate that Coprinus comatus‐compound has significant protective effect against acute hepatotoxicity induced by CCl4 , and has been supported by the evaluation of liver histopathology in mice .%探讨鸡腿菇复合制剂的护肝作用,为鸡腿菇复合制剂的推广应用提供理论基础.通过对昆明小鼠灌胃不同剂量的鸡腿菇复合制剂,测定小鼠的转氨酶(GOT ,GPT)、丙二醛(MDA)、抗氧化酶(SOD ,GSH‐PX )水平,观察肝脏的组织病理变化,研究鸡腿菇复合制剂对CCl4造成的急性肝损伤小鼠肝脏的保护作用.结果表明,灌胃鸡腿菇复合制剂可明显降低血清中转氨酶(GOT ,GPT)和肝脏中丙二醛(MDA)的水平(P<0.05),提高肝脏中抗氧化酶(SOD ,GSH‐PX )的水平.病理组织切片显示,造模小鼠肝组织存在大面积坏死区域和脂滴累积,鸡腿菇复合制剂在低、中、高三个剂量时均可减轻肝组织受损程度,其中低剂量的效果更为明显,说明鸡腿菇复合制剂对C C l4所致急性肝损伤小鼠肝脏具有明显的保护作用.【期刊名称】《西北师范大学学报(自然科学版)》【年(卷),期】2015(000)006【总页数】5页(P83-87)【关键词】鸡腿茹复合制剂;CCl4;肝脏;保护【作者】刘芹;耿雪冉;许瀛引;柳万石;王贺祥【作者单位】河南省农业科学院植物营养与资源环境研究所,河南郑州 450002;中国农业大学农业生物技术国家重点实验室,北京 100193;中国农业大学农业生物技术国家重点实验室,北京 100193;中国农业大学农业生物技术国家重点实验室,北京 100193; 金亨稷师范大学,平壤 999093;中国农业大学农业生物技术国家重点实验室,北京 100193【正文语种】中文【中图分类】R965*通讯联系人,男,教授,博士.主要研究方向为药用与食用真菌.E-mail:**************.cnE-mail:******************Key words:Coprinus comatus-compound;CCl4;liver;protection肝脏是人体最大、功能最复杂的实质性腺体,参与消化、代谢、解毒和免疫等多个过程[1].各种致病因子如机械损伤、病毒感染、化学毒物(CCl4、酒精等)、寄生虫感染以及高脂食物等均能引起肝细胞受损,导致肝脏疾病发生[2].近年来对化学性肝损伤有保护作用的天然药物的研究备受关注,显示了天然药物抗肝损伤、护肝降酶的美好前景[3,4].鸡腿菇复合制剂主要是由鸡腿菇等多种食用菌及中草药组成,是一种功能性食品,由于其具有作为天然药物的潜力,目前正处于研究和申报阶段.本研究利用CCl4建立肝损伤模型,探究此制剂对小鼠肝脏的保护作用及其可能的机制,为其进一步开发为天然药物提供理论基础.1.1 药品及主要试剂鸡腿菇复合制剂由苏州佛果生物科技有限公司提供,主要成分为鸡腿菇、猴头菇、金针菇、草菇、香菇、茯苓、人参、枸杞子、佛手等.谷草转氨酶(Glutamic oxalacetic transaminase,GOT)、谷丙转氨酶(Glutamate pyruvate transaminase,GPT)、丙二醛(Malondialdehyde,MDA)、超氧化物歧化酶(Superoxide dismutase,SOD)和谷胱甘肽过氧化物酶(Glutathione peroxidase,GSH-PX)检测试剂盒购自南京建成生物工程研究所,四氯化碳购自北京化工厂,水飞蓟素胶囊来自德国马博士大药厂.1.2 方法1.2.1 实验动物雄性昆明小鼠,体重18~22 g,由北京兴隆实验动物养殖厂提供.动物实验设施持续保持屏障环境标准.主要控制温度(25±2)℃,相对湿度55%±5%,光照明∶暗= 12 h∶12 h.动物饲养在标准盒内,每周两次更换垫料和笼具,保持盒内环境清洁干燥,每日添加饲料和饮水,保持动物自由饮食活动.实验遵循中国农业大学实验动物道德规范.1.2.2 动物实验及指标检测取雄性成年昆明小鼠54只,随机分成正常对照组、阴性对照组、阳性对照组、低剂量组、中剂量组和高剂量组.正常对照组不做任何处理,阴性对照组给予生理盐水(20 ml·kg-1·d-1,ig),阳性对照组灌胃给药水飞蓟素(200 mg·kg-1·d-1,ig),低剂量组、中剂量组和高剂量组分别灌胃770,1 540,3 080 mg·kg-1·d-1的鸡腿菇复合制剂.连续给药10 d后,除正常对照组外各组均灌胃CCl4的花生油溶液(1%,5 mL·kg-1,ig)[5,6].禁食不禁水16 h后,将小鼠摘除眼球取血,5 000 r·min-1离心10 min,取血清.按照试剂盒操作方法,检测血清中GOT和GPT的水平.分离小鼠的肝脏,用冰生理盐水制备肝脏匀浆(10%,w/v),8 000 r·min-1,4 ℃,离心10 min,按照试剂盒操作方法,检测血清中的MDA含量和SOD、GSH-PX活性.同时取肝脏左小叶组织,保存在10%中性福尔马林溶液中,用于肝脏组织病理学检查.1.2.3 肝脏组织病理学检查上述固定的各组小鼠肝组织块,系列乙醇脱水,常规石蜡包埋、切片(4 μm),H&E染色,生物显微镜观察.1.3 统计学分析实验数据采用SPSS 20.0软件进行统计学分析,实验数据以均数±标准差±s)表示,组内差异采用方差分析,组间差异采用t检验,以P<0.05为有统计学意义.2.1 鸡腿菇复合制剂对小鼠血清GOT和GPT活性的影响与正常对照组相比,CCl4造模后的小鼠血清GOT、GPT水平明显上升,与正常对照组相比均有极显著的差异(P<0.01),说明模型成功.与阴性对照组相比,灌胃低、中、高三个剂量的鸡腿菇复合制剂均可明显降低血清中GOT和GPT活力(P<0.05),尤其是灌胃低剂量的鸡腿菇复合制剂后,小鼠血清中的GOT、GPT活力有更明显的降低趋势(P<0.01)(表1).2.2 鸡腿菇复合制剂对小鼠肝脏MDA含量和SOD、GSH-PX活性的影响与正常对照组相比,造模后的小鼠肝脏MDA水平明显上升,差异极显著(P<0.01),灌胃低、中、高三个剂量的鸡腿菇复合制剂均可降低肝脏MDA的水平(P<0.05).造模后小鼠肝脏中抗氧化酶SOD和GSH-PX水平与正常对照组相比明显下降,差异极显著(P<0.01),低、中、高三个剂量的测试样品均有提高SOD和GSH-PX水平的作用,尤其是低剂量组与模型组相比有显著性差异(P<0.05,表2).2.3 肝组织病理学变化组织病理切片显示,正常组的小鼠肝脏组织完好,肝细胞完整,形状规则,排列紧密、均一,细胞核正常(图1:A).阴性对照组小鼠肝脏严重受损,表现为大面积坏死区域和脂滴累积(图1:B).阳性药物水飞蓟素能明显改善CCl4对肝细胞的毒害作用,使肝细胞基本恢复正常(图1:C).鸡腿菇复合制剂的低、中、高三个剂量均可减少肝脏受损害的程度,尤其是低剂量的效果更为明显,基本无肝细胞脂肪变性和坏死(图1:D~F),这说明鸡腿菇复合制剂对CCl4所致急性肝损伤小鼠有较好的保护作用.肝脏在维持人体健康中有着十分重要的地位.CCl4造成的肝损伤主要是因为其经肝线粒体细胞色素P450作用后生成的三氯甲烷自由基可与蛋白质共价结合导致蛋白质合成障碍以及脂质分解代谢紊乱,从而引起肝细胞内甘油三酯累积.同时三氯甲烷自由基与O2结合生成的过氧化三氯甲烷自由基会导致脂质过氧化,破坏细胞膜结构,最终导致肝细胞无法正常代谢而死亡[3,5,7].血清GOT和GPT活力水平是反应肝损伤的灵敏指标,其水平的高低与肝脏受损的程度一致[3].正常情况下,GOT和GPT主要存在于肝细胞中,血清内含量很低,而当肝细胞受到损害时,这些酶会从细胞中释放出来而进入血循环中[8-10].本实验中CCl4造模后小鼠血清GOT、GPT活力水平明显上升,与正常对照组相比均有极显著的差异.而鸡腿菇复合制剂在低、中、高三个剂量下都可以降低血清GOT 和GPT活力水平,说明鸡腿菇复合制剂具有保护肝脏的作用.MDA是脂质过氧化的代谢产物,常用作脂质过氧化的指标.MDA能够进入膜脂的水相,与膜蛋白、膜磷脂上的-NH2交联形成Schiff碱,从而导致细胞膜变硬,流动性减低,通透性增加,从而使膜的功能受损或降低,故而通过检测其水平的高低可以反映机体氧化损伤的程度[2,3].SOD是生物体内清除自由基、抑制自由基反应的物质之一,它可以催化超氧阴离子还原成过氧化氢和氧气从而终止自由基链式反应,对机体细胞氧化损伤具有很强的防御功能[11,12].GSH-PX是机体内广泛存在的一种重要的催化过氧化氢分解的酶,它特异的催化过氧化氢还原为水和氧气,具有保护细胞膜结构和功能完整的作用,而在肝损伤发生的过程中,可以起到减轻肝细胞膜损害的作用[8,13].抗氧化酶SOD和GSH-PX组成了防止氧化损伤的第一道防线,其水平的高低直观地反映了组织的氧化应激能力[14].本实验中灌胃鸡腿菇复合制剂可以拮抗CCl4造成的肝脏MDA水平的升高以及抗氧化酶SOD和GSH-PX活力水平的降低,同时结合组织病理学检查结果可知,鸡腿菇复合制剂对CCl4所致的急性肝损伤小鼠的肝脏具有明显的保护作用,并且其保肝作用可能是通过增强机体内源性抗氧化防御系统,有效地拮抗CCl4所致的抗氧化酶活性降低,从而抑制自由基介导的脂质过氧化反应来实现[15,16].根据文献报道及本实验的预实验,建立了小鼠的CCl4急性肝损伤模型,实验模型组转氨酶和MDA水平明显高于正常对照组,且抗氧化酶SOD和GSH-PX活力水平较正常对照组明显降低也证实了模型的可信度.在本实验条件下,鸡腿菇复合制剂尤其是在低剂量下可以降低血清转氨酶及肝组织MDA的水平,同时提高抗氧化酶的水平,组织病理学检查也显示鸡腿菇复合制剂可以明显减轻CCl4对肝脏造成损害的程度,具有保护肝脏的作用.【相关文献】[1] ALTAS S,KIZIL G,KIZIL M,et al.Protective effect of Diyarbakir watermelon juice on carbon tetrachloride-induced toxicity in rats[J].Food Chem Toxicol,2011,49(9):2433.[2] LU X,ZHAO Y,SUN Y,et al.Characterisation of polysaccharides from green tea of Huangshan Maofeng with antioxidant and hepatoprotective effects[J].FoodChem,2013,141(4):3415.[3] CHENG N,REN N,GAO H,et al.Antioxidant and hepatoprotective effects of Schisandra chinensis pollen extract on CCl4-induced acute liver damage in mice[J].Food Chem Toxicol,2013,55:234.[4] KEPEKCI R A,POLAT S,CELIK A,et al.Protective effect of Spirulina platensis enriched in phenolic compounds against hepatotoxicity induced by CCl4[J].FoodChem,2013,141(3):1972.[5] HUANG G J,DENG J S,HUANG S S,et al.Hepatoprotective effects of eburicoic acid and dehydroeburicoic acid from Antrodia camphorata in a mouse model of acute hepatic injury[J].Food Chem,2013,141(3):3020.[6] KIM Y,YOU Y,YOON H G,et al.Hepatoprotective effects of fermented Curcuma longa L on carbon tetrachloride-induced oxidative stress in rats[J].Food Chem,2014,151:148. [7] GAN D,MA L,JIANG C,et al.Medium optimization and potential hepatoprotective effect of mycelial polysaccharides from Pholiota dinghuensis Bi against carbon tetrachloride-induced acute liver injury in mice[J].Food Chem Toxicol,2012,50(8):2681. [8] JIANG C,XIONG Q,GAN D,et al.Antioxidant activity and potential hepatoprotective effect of polysaccharides from Cyclina sinensis[J].Carbohydr Polym,2013,91(1):262.[9] LIU Q,TIAN G,YAN H,et al.Characterization of polysaccharides with antioxidant and hepatoprotective activities from the wild edible mushroom Russula vinosa Lindblad[J].J Agric Food Chem,2014,62(35):8858.[10] HUANG G J,DENG J S,HUANG S S,et al.Protective effect of antrosterol from Antrodia camphorata submerged whole broth against carbon tetrachloride-induced acute liver injury in mice[J].Food Chem,2012,132(2):709.[11] ZHAO W,LI J J,YUE S Q,et al.Antioxidant activity and hepatoprotective effect of a polysaccharide from Bei Chaihu(Bupleurum chinense DC)[J].CarbohydrPolym,2012,89(2):448.[12] YU J,CUI P J,ZENG W L,et al.Protective effect of selenium-polysaccharides from the mycelia of Coprinus comatus on alloxan-induced oxidative stress in mice[J].Food Chem,2009,117(1):42.[13] SABIR S M,AHMAD S D,HAMID A,et al.Antioxidant and hepatoprotective activity of ethanolic extract of leaves of Solidago microglossa containing polyphenolic compounds[J].Food Chem,2012,131(3):741.[14] WANG D,ZHAO Y,JIAO Y,et al.Antioxidative and hepatoprotective effects of the polysaccharides from Zizyphus jujube cv.Shaanbeitanzao[J].CarbohydrPolym,2012,88(4):1453.[15] SOARES A A,DE SA-NAKANISHI A B,BRACHT A,et al.Hepatoprotective effects of mushrooms[J].Molecules,2013,18(7):7609.[16] TUNG Y T,WU J H,HUANG C C,et al.Protective effect of Acacia confusa bark extract and its active compound gallic acid against carbon tetrachloride-induced chronic liver injury in rats[J].Food Chem Toxicol,2009,47(6):1385.。

  1. 1、下载文档前请自行甄别文档内容的完整性,平台不提供额外的编辑、内容补充、找答案等附加服务。
  2. 2、"仅部分预览"的文档,不可在线预览部分如存在完整性等问题,可反馈申请退款(可完整预览的文档不适用该条件!)。
  3. 3、如文档侵犯您的权益,请联系客服反馈,我们会尽快为您处理(人工客服工作时间:9:00-18:30)。

113Induction of monooxygenases by annatto and bixin Induction of liver monooxygenasesby annatto and bixin in female ratsLaboratório de Toxicologia Ambiental, Escola Nacional de Saúde Pública,Fundação Oswaldo Cruz, Rio de Janeiro, RJ, BrasilA.C.A.X. De-Oliveira,I.B. Silva,D.A. Manhães-Rocha and F.J.R. PaumgarttenAbstractAnnatto or urucum is an orange-yellow dye obtained from Bixa orellana seeds. It has been used as a natural dye in a variety of food products, drugs and cosmetics, and also in Brazilian cuisine as a condiment ( colorau ). Bixin, a carotenoid devoid of provitamin A activity, is the main pigment found in annatto. Some carotenoids (canthaxanthin, astaxanthin and ß-Apo-8'-carotenal) are known to be potent inducers of CYP1A1, a property not shared by others (ß-carotene, lycopene and lutein). Little is known, however, about the CYP1A1-inducing properties of bixin and annatto. The present study was performed to determine the effects of an annatto extract (28%bixin) and bixin (95% pure) on rat liver monooxygenases. Adult female Wistar rats were treated by gavage with daily doses of annatto (250 mg/kg body weight, which contains approximately 70 mg bixin/kg body weight), bixin (250 mg/kg body weight) or the vehicle only (corn oil, 3.75 g/kg body weight) for 5 consecutive days, or were not treated (untreated control). The activities of aniline-4-hydroxylase (A4H), ethoxycoumarin-O -deethylase (ECOD), ethoxy- (EROD), meth-oxy- (MROD), pentoxy- (PROD) and benzyloxy- (BROD) resorufin-O -dealkylases were measured in liver microsomes. Annatto (250 mg/kg containing 70 mg bixin/kg) induced EROD (3.8x), MROD (4.2x),BROD (3.3x) and PROD (2.4x). Bixin (250 mg/kg) was a weaker inducer of EROD (2.7x), MROD (2.3x) and BROD (1.9x) and did not alter PROD, A4H or ECOD activities. These results suggest that constituents of the extract other than bixin play an important role in the induction of CYP1A and CYP2B observed with annatto food colorings.CorrespondenceF.J.R. P aumgarttenLaboratório de Toxicologia Ambiental Escola Nacional de Saúde Pública FIOCRUZ Av. Brasil, 436521045-900 Rio de Janeiro, RJ BrasilFax: +55-21-2260-1069E-mail: paum@ensp.fiocruz.br Research supported byP AP ES-FIOCRUZ. F.J.R. P aumgartten,I.B. Silva (PIBIC, FIOCRUZ) and D.A. Manhães-Rocha (IC, CNPq)are recipients of fellowships from CNPq.Received April 5, 2002Accepted October 7, 2002Key words·Food additive ·Natural color·Cytochrome P450·Drug metabolizing enzymes ·Carotenoids ·BixaceaeAnnatto is an orange-yellow dye obtained from the pericarp of seeds from Bixa orellana L. (Bixaceae), a tree native to Central and South America tropical forests (1,2). In Bra-zil annatto is known as urucum or urucu ,a word from the Tupi-Guarani language, and in Spanish-speaking America as achiote from the Aztec achiotl (1). The use of annatto by the New World man dates back to ancient times. The indigenous Amazon people have used urucum for body painting for centuries and it is believed that the origi-nal Aztec chocolate beverage contained an-natto seeds in addition to cocoa. Moreover,seeds and leaves of the annatto tree were used by the Aztecs to prepare remedies for a variety of illnesses such as tonsillitis, asthma,pleurisy, rectal disorders, headache, jaun-dice, sunstroke, and burns.Bixin (cis -bixin, CAS 6983-79-5) is the main oil-soluble pigment of B. orellana seeds.It is a carotenoid devoid of provitamin ABrazilian Journal of Medical and Biological Research (2003) 36: 113-118ISSN 0100-879X Short Communication114A.C.A.X. De-Oliveira et al.activity with two carboxylic groups, one of which is a methyl ester (Figure 1). Hydroly-sis of this methyl ester group yields the corresponding dicarboxylic acid, norbixin,which is an annatto pigment soluble in aque-ous alkaline solutions. Annatto extracts, as well as their major carotenoid constituents bixin and norbixin, have been widely em-ployed as color additives in food, drugs and cosmetics (3,4). As a food coloring, annatto has been added to butter, cheese, sausages,margarine, ice-cream, cereals and to a vari-ety of other products (3,4). In Northern and Northeastern Brazil, an annatto extract (known as colorau or colorífico ) is also extensively used as a food condiment.Carotenoids such as canthaxanthin, asta-xanthin and ß-Apo-8'-carotenal but not ß-carotene or lycopene, have been reported to be potent inducers of CYP1A1 isoenzymes in rats (5-8) and mice (9). The effects of bixin on xenobiotic metabolizing enzymes,however, have been much less studied. Jewell and O Brien (8) found that bixin (300 mg/kg diet for 16 days) increased ethoxy- (EROD;a marker for CYP1A1), methoxy- (MROD;CYP1A2) and, to a lesser extent, pentoxy-resorufin-O -dealkylases (PROD; CYP2B1)in the rat liver. To our knowledge, no other report has been published on the effects ofbixin and annatto on cytochrome P450 en-zymes. The present study was undertaken to investigate the effects of bixin as well as those of an annatto food coloring on the activities of liver monooxygenases in the rat.Virgin female Wistar rats, approximately 100 days old and weighing 220-260 g, from the CECAL-FIOCRUZ breeding stock were used. The rats were housed four per cage in standard plastic cages with stainless steel cover lids and wood shavings as bedding.The animals were given free access to a rodent pelleted diet (Nuvital ®, Nuvilab,Curitiba, PR, Brazil) and tap water and were kept under conditions of constant tempera-ture (22 ± 1ºC), humidity (approximately 70%) and photoperiod (12-h light and 12-h dark, lights on 8:00 am). The research proto-col was approved by the Ethics Committee on the Use of Animals of Oswaldo Cruz Foundation (CEUA-FIOCRUZ). Annatto (containing 28% bixin, determined spectro-photometrically) was supplied by BaculerêAgro Industrial Ltda., Olimpia, SP, Brazil,and bixin (purity 95%) was from Helianthus S.A., Lima, Peru.The rats were treated by gastric gavage with daily doses of annatto (250 mg kg body weight -1 day -1 containing 70 mg bixin/kg),bixin (250 mg kg body weight -1 day -1), or theCOOHCOOCH 3Non-inducersCYP1A inducersLuteinß-Apo-8’-carotenalß-CaroteneAstaxanthinBixinOHOHOHOHOOO HOO115 Induction of monooxygenases by annatto and bixinvehicle only (corn oil, 3.75 g kg body weight-1 day-1) for 5 consecutive days. One untreated control group was also run in par-allel.All food was withdrawn after the last dose and the animals were killed by cervical dislocation 16 h later. After killing, livers were immediately removed, freed from fat and extra tissue and weighed. Liver tissue was homogenized with ice-cold 250 mM sucrose in a glass Potter Elvejhem homog-enizer with a Teflon pestle. The homogenate was centrifuged at 9,000 g for 30 min and the supernatant obtained was ultracentrifuged at 100,000 g for 60 min. The pellet was resus-pended in 100 mM Tris-HCl buffer, pH 7.4, and ultracentrifuged again at 100,000 g for 60 min. The final pellet (microsomal frac-tion) was then suspended in an ice-cold solu-tion consisting of 0.1 mM EDTA, 20% glyc-erol potassium phosphate buffer (100 mM, pH 7.4) and stored in liquid nitrogen until further use. Protein concentration in the mi-crosomal fraction was quantified by the method of Bradford (10).Alcoxyresorufin-O-dealkylase activities were determined spectrofluorometrically as described by Burke et al. (11) except that an NADPH regenerating system was used (12). 7-Ethoxycoumarin-O-deethylase (ECOD) ac-tivity was determined as reported by Greenlee and Poland (13) with some minor modifica-tions. Aniline-4-hydroxylase (A4H) was de-termined spectrophotometrically as described in detail by Gibson and Skett (14). Sub-strates (pentoxyresorufin, ethoxyresorufin, methoxyresorufin and benzyloxyresorufin, aniline and 7-ethoxycoumarin), reaction products (resorufin, 4-aminophenol and umbelliferone), glucose-6-phosphate, NADP and glucose-6-phosphate dehydrogenase were all from Sigma (St. Louis, MO, USA).Neither annatto (28% bixin) nor bixin (95% pure) given orally at a dose as high as 250 mg kg body weight-1 day-1 for 5 consecu-tive days was overtly toxic to the rats. It should be pointed out that, in a preliminary dose range-finding experiment, 250 mg/kg body weight was half the highest dose of this powdered annatto extract that was feasible to give by gavage to rats.As shown in Table 1, annatto (250 mg/kg116 A.C.A.X. De-Oliveira et al.body weight containing 70 mg bixin/kg body weight) caused an increase in the activities of EROD (3.8x), MROD (4.2x), benzylox-yresorufin-O-dealkylases (BROD) (3.3x) and PROD (2.4x), as compared to the activities found for the vehicle control group. Since in rat liver microsomes EROD and MROD are reactions predominantly catalyzed by CYP1A1 and 1A2, and PROD as well as BROD are catalyzed by isoenzymes belong-ing to the 2B subfamily (15), the foregoing findings suggest that annatto (28% bixin) induced CYP1A1/2 and, to a lesser extent, CYP2B. A slight enhancement of EROD (2.7x), MROD (2.3x) and BROD (1.9x) was also noted among rats treated with 95% pure bixin (250 mg/kg body weight) (Table 1). The administration of bixin, however, did not change the activities of PROD, ECOD or A4H (Table 1). In rat liver microsomes, the O-deethylation of ethoxycoumarin seems to be catalyzed by several CYP450 isoforms including those belonging to subfamilies 1A, 2A, 2B, 2C, 2E and 3A (16,17). Since EROD is more specific for CYP1A1 than ECOD, the weak inducing effect noted in bixin-treated rats was revealed by deethylation reaction of the former but not of the latter. The hydroxylation of aniline at carbon 4, on the other hand, is predominantly catalyzed by CYP2E1 (16,18).Our results show that bixin, under the conditions of this study, did not alter CYP2E1 causing only a slight increase in the activities of CYP1A1/2 and 2B. It is noteworthy that the induction of CYP1A and 2B in annatto-treated rats was stronger than that found in rats treated with 95% pure bixin. Since the dose of bixin administered to the former group (70 mg/kg body weight) was approxi-mately three times lower than that given to the latter group (250 mg/kg body weight), these results suggest that constituents of the annatto extract other than bixin were at least partially responsible for the induction of CYP1A1/2 and 2B. A weak inducing effect of bixin, however, cannot be ruled out.However, it seems unlikely that any liver monooxygenase induction occurs when an-natto and bixin are used as food colorings. The daily doses of annatto (70 mg bixin kg body weight-1 day-1) and bixin (250 mg kg body weight-1 day-1) that caused only a weak enzyme induction in the present study were 1077 and 3846 times, respectively, the cur-rent acceptable daily intake established for annatto/bixin (0.065 mg bixin kg body weight-1 day-1) (3). Thus, it seems unlikely that any enzyme induction or change in drug metabolism may occur at daily doses result-ing from the current use of annatto/bixin as food colorings.Our results with regard to bixin are, to a certain extent, at variance with those re-ported by Jewell and O Brien (8). These investigators found that EROD (CYP1A1) and MROD (CYP1A2) activities were mark-edly increased in rats fed a bixin-enriched diet (300 mg/kg diet) for 16 days (8). Differ-ences between the two studies with regard to the effects of bixin on EROD, MROD and PROD could have been due to differences in the method of administration (gavage versus diet), gender (female versus male rats), and/ or in the duration of exposure (5 versus 16 days). The daily dose of bixin in the present study, however, was at least five times higher than that given by Jewell and O Brien (45 mg kg body weight-1 day-1) (8). It is of note that the induction of EROD, MROD and PROD observed by Jewell and O Brien (8) was similar to that caused by the less pure annatto extract (28% bixin) used in our study. Since the origin of bixin added to the diet in the Jewell and O Brien s study was a com-mercial annatto extract (Annatto R35) con-taining only 42 g of bixin per kg of powder (4.2% of bixin), enzyme induction could have been due to impurities or constituents of the extract other than bixin. Inducers of CYP1A and 2B have been found in crucifer-ous vegetables (broccoli, cabbage, Brussels sprouts) and garlic (Allium species), and in the essential oils of a large variety of plants117 Induction of monooxygenases by annatto and bixin(12,19,20).The rather weak effect of bixin on rat liver monooxygenases belonging to the CYP1A subfamily, on the other hand, indi-cated that this carotenoid, like ß-carotene, lycopene and lutein, does not share the po-tent CYP1A1/2-inducing properties of apo-or oxocarotenoids such as ß-Apo-8'-carote-nal, canthaxanthin and astaxanthin (6,7). The mechanism underlying CYP1A induction by carotenoids is still unclear. Experiments on mice have demonstrated that canthaxanthin, like polycyclic aromatic hydrocarbons and 2,3,7,8 tetrachlorodibenzodioxin (TCDD), induces CYP1A1 and CYP1A2 through an Ah-receptor pathway (9). In mice, ß-Apo-8'-carotenal seems to induce specifically CYP1A2 (9). Canthaxantin and ß-Apo-8'-carotenal, however, did not compete with TCDD for the TCDD-binding site of the cytosolic Ah-receptor of mice (9).As shown in Figure 1, there are no evi-dent structural features separating the caro-tenoids which are potent inducers of CYP1A1/2 from those which do not act as inducers of these microsomal enzymes. Ow-ing to this apparent lack of a structure-activ-ity relationship, Gradelet et al. (9) advanced the hypothesis that common or similar me-tabolites of the three carotenoids (ß-Apo-8'-carotenal, canthaxanthin and astaxanthin) -and not the parent compounds themselves -are the ultimate inducing molecules. Never-theless, little is known about the transforma-tion of carotenoids in mammals, and it is still unclear which metabolites could be involved in the induction of liver microsomal en-zymes.Results from the present study showed that an annatto food coloring (28% bixin), given at oral doses as high as 250 mg kg-1 day-1 for 5 consecutive days, induced CYP1A and 2B subfamilies in the rat liver. Since a weaker induction was noted when rats re-ceived a similar treatment with bixin (95% pure), it seems fair to conclude that constitu-ents of the annatto extract other than bixin played an important role in the induction of CYP1A and 2B.AcknowledgmentsThe authors are indebted to BaculerêAgroindustrial Ltda., Helianthus S.A. and the Center for Natural Colors (NCN, Brazil) for supplying annatto extracts, bixin and some reagents used in this study.References1.Camargo MTLA (1985). Medicina Popular: Aspectos Metodológicospara Pesquisa, Garrafada, Objeto de Pesquisa, Componentes Medicinais de Origem Vegetal, Animal e Mineral. ALMED Editora e Livraria Ltda., São Paulo, SP, Brazil.2.Di Stasi LC, Santos EMG, Dos-Santos CM & H iruma CA (1989).Plantas Medic inais da Amazônia. Editora UNESP, São Paulo, SP, Brazil.3.JECFA (1982). Evaluation of certain food additives and contami-nants. Twenty-sixth Report of the Joint FAO/WHO Expert Commit-tee on Food Additives. Technical Report Series, No. 683.4.Hallagan JB, Allen DC & Borzelleca JF (1995). The safety and regula-tory status of food, drug and cosmetic colour additives exempt from certification. Food and Chemical Toxicology, 33: 515-528.5.Astorg P, Gradelet S, Leclerc J, Canivenc MC & Siess MH (1994).Effects of beta-carotene and canthaxanthin on liver xenobiotic-me-tabolizing enzymes in the rat. Food and Chemic al Toxic ology, 32: 735-742.6.Gradelet S, Astorg P, Leclerc J, Chevalier J, Vernevaut MF & SiessMH (1996). Effects of canthaxanthin, astaxanthin, lycopene and lutein on liver xenobiotic-metabolizing enzymes in the rat. Xenobio-tica, 26: 49-63.7.Gradelet S, Leclerc J, Siess MH & Astorg P (1996). Beta-Apo-8'-carotenal, but not beta-carotene, is a strong inducer of liver cyto-chromes P4501A1 and 1A2 in the rat. Xenobiotica, 26: 909-919. 8.Jewell C & O’Brien NM (1999). Effect of dietary supplementationwith carotenoids on xenobiotic metabolizing enzymes in the liver, lung, kidney and small intestine of the rat. British Journal of Nutri-tion, 81: 235-242.9.Gradelet S, Astorg P, Pineau T, Canivenc M-C, Siess M-H, Leclerc J& Lesca P (1997). Ah receptor-dependent CYP1A induction by two carotenoids, canthaxanthin and ß-Apo-8'-carotenal, with no affinity for the TCDD binding site. Biochemical Pharmacology, 54: 307-315.10.Bradford MM (1976). A rapid and sensitive method for the quantita-tion of microgram quantities of protein utilizing the principle of protein dye binding. Analytical Biochemistry, 72: 248-254.11.Burke MD, Thompson S, Elcombe CR, H alpert J, H aaparanta T &118 A.C.A.X. De-Oliveira et al.Mayer RT (1985). Ethoxy-, penthoxy- and benzyloxyphenoxazones and homologues: a series of substrates to distinguish between different induced-cytochromes P-450. Bioc hemic al Pharmac ology, 34: 3337-3345.12.De-Oliveira ACAX, Ribeiro-Pinto LF, Otto SS, Gonçalves A & Paum-gartten FJR (1997). Induction of liver monooxygenases by ß-myrcene. Toxicology, 124: 135-140.13.Greenlee WF & Poland A (1978). An improved assay of 7-ethoxycoumarin O-deethylase activity: induction of hepatic enzyme activity in C57BL/6J and DBA/2J mice by phenobarbital, 3-methyl-cholanthrene and 2,3,7,8-tetrachlorodibenzo-p-dioxin. Journal of Pharmacology and Experimental Therapeutics, 205: 596-605.14.Gibson GG & Skett P (1994). Introduction to Drug Metabolism. 2ndedn. Blackie Academic & Professional/Chapman & H all, London, England.15.Burke MD, Thompsom S, Weaver RJ, Wolf CR & Mayer RT (1994).Cytochrome P450 specificities of alkoxyresorufin-O-dealkylation in human and rat liver. Biochemical Pharmacology, 48: 923-936.16.Funae Y & Imaoka S (1993). Cytochrome P450 in rodents. In:Schenkman JB & Greim H (Editors), Handbook of Experimental Pharmacology. 105, Cytochrome P450. Springer-Verlag, Heidelberg, Germany.17.Klinger W, Lupp A, Karge E, Baumbach H, Eichhorn F, Feix A, FulnerF, Gernhardy S, Knels L, Kost B, Mertens G, Werner F, Oettel M, Romer W, Schwarz S, Elger W & Schneider B (2002). Estradiol, testosterone, dehydroepiandrosterone and androstenedione: novel derivatives and enantiomers. Interactions with rat liver microsomal cytochrome P450 and antioxidant/radical scavenger activities in vi-tro. Toxicology Letters, 128: 129-144.18.Hashemi E, Till C & Ioannides C (2000). Stability of cytochrome P450proteins in cultured precision-cut rat liver slices. Toxicology, 149: 51-61.19.H iroi T, Myiazaki Y, Kobayashi Y, Imaoka S & Funae Y (1995).Induction of hepatic P450s in rat by essential wood and leaf oils.Xenobiotica, 25: 457-467.20.Okey AB, Riddick DS & Harper PA (1994). The Ah receptor: mediatorof the toxicity of 2,3,7,8-tetrachlorodibenzo-p-dioxin (TCDD) and re-lated compounds. Toxicology Letters, 70: 1-22.。

相关文档
最新文档